2440 RESEARCH BLVD, ROCKVILLE, MD
Annual General Meeting of Shareholders
2026 Omnibus Share Incentive Plan
Appoints Dr. Srishti Gupta as Chief Executive Officer
Change in Certifying Accountants
Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer
Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value
Reports Full Year 2025 Financial Results and Provides Business Update
Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer
Amended Annual and Transition Report of Foreign Private Issuers
Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
No filings found
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Registration Statement for Depositary Shares, Issued upon Effectiveness
Submission Upload
Correspondence